BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
- Status
- COMPLETED
- Phase
- PHASE3
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE1
Trial Of Pembrolizumab And Nintedanib
- Status
- COMPLETED
- Phase
- PHASE1
Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
- Status
- COMPLETED
- Phase
- PHASE2
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
- Status
- COMPLETED
- Phase
- PHASE3
Special Combination of BBI608 and Pembrolizumab
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients
- Status
- COMPLETED
- Phase
- PHASE2
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
- Status
- COMPLETED
- Phase
- PHASE2
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)
- Status
- COMPLETED
- Phase
- PHASE1